Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

A. Bayle; M. Khettab; F. Lucibello; A. N. Chamseddine; V. Goldschmidt; A. Perret; S. Ropert; F. Scotté; P. Loulergue; O. Mir

doi:10.1016/j.annonc.2020.03.290

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

A. Bayle, M. Khettab, F. Lucibello, A. N. Chamseddine, V. Goldschmidt, A. Perret, S. Ropert, F. Scotté, P. Loulergue, O. Mir

Research output: Contribution to journal › Letter › peer-review

30 Citations (Scopus)

Original language	English
Pages (from-to)	959-961
Number of pages	3
Journal	Annals of Oncology
Volume	31
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2020.03.290
Publication status	Published - 1 Jul 2020

Access to Document

10.1016/j.annonc.2020.03.290

Cite this

@article{b9050c7089424f22a73b74bf18337f93,

title = "Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1",

author = "A. Bayle and M. Khettab and F. Lucibello and Chamseddine, {A. N.} and V. Goldschmidt and A. Perret and S. Ropert and F. Scott{\'e} and P. Loulergue and O. Mir",

note = "Funding Information: None. OM has acted as consultant for Blueprint Medicines, Eli-Lilly, Janssen, Lundbeck, Pfizer, Roche, Servier and Vifor Pharma; as a speaker for Eli-Lilly, Roche, Servier, Medscape and PrimeOncology; and owns stock options from Amplitude Surgical, Transgene and Ipsen. SR has acted as consultant for Bayer Healthcare, Novartis and Sanofi-Aventis. Other authors have no conflict of interest to declare.",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2020.03.290",

language = "English",

volume = "31",

pages = "959--961",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "7",

}

TY - JOUR

T1 - Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

AU - Bayle, A.

AU - Khettab, M.

AU - Lucibello, F.

AU - Chamseddine, A. N.

AU - Goldschmidt, V.

AU - Perret, A.

AU - Ropert, S.

AU - Scotté, F.

AU - Loulergue, P.

AU - Mir, O.

N1 - Funding Information: None. OM has acted as consultant for Blueprint Medicines, Eli-Lilly, Janssen, Lundbeck, Pfizer, Roche, Servier and Vifor Pharma; as a speaker for Eli-Lilly, Roche, Servier, Medscape and PrimeOncology; and owns stock options from Amplitude Surgical, Transgene and Ipsen. SR has acted as consultant for Bayer Healthcare, Novartis and Sanofi-Aventis. Other authors have no conflict of interest to declare.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85086328577&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.03.290

DO - 10.1016/j.annonc.2020.03.290

M3 - Letter

C2 - 32224150

AN - SCOPUS:85086328577

SN - 0923-7534

VL - 31

SP - 959

EP - 961

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

Access to Document

Other files and links

Cite this